{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:23:41Z","timestamp":1787743421698,"version":"build-2784847793"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.msard.2022.103919","type":"journal-article","created":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T09:52:49Z","timestamp":1653817969000},"page":"103919","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Clinical and paraclinical profile of neuromyelitis optic spectrum disorder in a peruvian cohort"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0313-3987","authenticated-orcid":false,"given":"Sheila","family":"Castro-Suarez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Guevara-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Osorio-Marcatinco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin","family":"Alvarez-Toledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Meza-Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar","family":"Capar\u00f3-Zamalloa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.msard.2022.103919_bib0001","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.rdc.2017.06.007","article-title":"Neuromyelitis Optica","volume":"43","author":"Patterson","year":"2017","journal-title":"Rheum. Dis. Clin. North Am."},{"issue":"9451","key":"10.1016\/j.msard.2022.103919_bib0002","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.msard.2022.103919_bib0003","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1212\/CON.0000000000000742","article-title":"Neuromyelitis Optica Spectrum Disorder and Other Non-Multiple Sclerosis Central Nervous System Inflammatory Diseases","volume":"25","author":"Flanagan","year":"2019","journal-title":"Continuum (Minneap Minn)"},{"issue":"24","key":"10.1016\/j.msard.2022.103919_bib0004","doi-asserted-by":"crossref","first-page":"e2265","DOI":"10.1212\/WNL.0000000000006645","article-title":"Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark","volume":"91","author":"Papp","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.103919_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102807","article-title":"Prevalence of neuromyelitis optica spectrum disorder in Belo Horizonte, Southeast Brazil","volume":"50","author":"Lana-Peixoto","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2022.103919_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103083","article-title":"Status of the neuromyelitis optica spectrum disorder in Latin America","volume":"53","author":"Rivera","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.msard.2022.103919_bib0007","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.msard.2022.103919_bib0008","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.msard.2022.103919_bib0009","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3390\/cells8020090","article-title":"Aquaporin-4 Water Channel in the Brain and Its Implication for Health and Disease","volume":"8","author":"Mader","year":"2019","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.msard.2022.103919_bib0010","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/biomedicines7020042","article-title":"Neuromyelitis Optica Spectrum Disorder and Anti-MOG Syndromes","volume":"7","author":"Lana-Peixoto","year":"2019","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.msard.2022.103919_bib0011","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.msard.2022.103919_bib0012","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.mayocp.2016.12.014","article-title":"Neuromyelitis Spectrum Disorders","volume":"92","author":"Weinshenker","year":"2017","journal-title":"Mayo Clin. Proc."},{"issue":"1","key":"10.1016\/j.msard.2022.103919_bib0013","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ncl.2020.09.003","article-title":"Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder","volume":"39","author":"Wallach","year":"2021","journal-title":"Neurol. Clin."},{"issue":"1","key":"10.1016\/j.msard.2022.103919_bib0014","doi-asserted-by":"crossref","first-page":"e6388","DOI":"10.5867\/medwave.2016.01.6388","article-title":"[Neuromyelitis optica spectrum disorders as initial presentation of Sj\u00f6gren's syndrome: A case report]","volume":"16","author":"Alva D\u00edaz","year":"2016","journal-title":"Medwave"},{"key":"10.1016\/j.msard.2022.103919_bib0015","article-title":"Pruritus as an initial symptom of Neuromyelitis Optica Spectrum Disorder. A Peruvian case report","author":"Valdivia","year":"2021","journal-title":"Neuroimmunology Reports"},{"key":"10.1016\/j.msard.2022.103919_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102173","article-title":"Neuromyelitis optica in patients with myasthenia gravis: Two case-reports","volume":"43","author":"Castro-Suarez","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"10.1016\/j.msard.2022.103919_bib0017","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bpa.12084","article-title":"Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature","volume":"23","author":"Jarius","year":"2013","journal-title":"Brain Pathol."},{"key":"10.1016\/j.msard.2022.103919_bib0018","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide","volume":"11","author":"Hor","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.msard.2022.103919_bib0019","article-title":"Clinical and radiological profile of neuromyelitis optica spectrum disorders in an Ecuadorian cohort","volume":"44","author":"Correa-Diaz","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2022.103919_bib0020","article-title":"Neuromyelitis optica spectrum disorder: Do patients positive and negative for anti-aquaporin-4 antibodies present distinct entities? A Colombian perspective","author":"Ortiz Salas","year":"2020","journal-title":"Neurologia (Engl Ed)"},{"issue":"5","key":"10.1016\/j.msard.2022.103919_bib0021","first-page":"193","article-title":"[Neuromyelitis optica spectrum disorders: profile of a cohort according to the 2015 diagnostic criteria]","volume":"65","author":"Uribe-San Martin","year":"2017","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.msard.2022.103919_bib0022","article-title":"Epidemiological findings of neuromyelitis optica spectrum disorders in a Venezuelan study","volume":"47","author":"de Ibis","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.msard.2022.103919_bib0023","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1590\/0004-282x20160193","article-title":"Neuromyelitis optica: phenotypic characteristics in a Brazilian case series","volume":"75","author":"Del Negro","year":"2017","journal-title":"Arq. Neuropsiquiatr."},{"issue":"5","key":"10.1016\/j.msard.2022.103919_bib0024","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s00415-008-0781-2","article-title":"Characteristics of Devic\u2019s disease (neuromyelitis optica) in Mexico","volume":"255","author":"Rivera","year":"2008","journal-title":"J. Neurol."},{"issue":"8\u20139","key":"10.1016\/j.msard.2022.103919_bib0025","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.neurol.2009.02.012","article-title":"[Descriptive epidemiology of neuromyelitis optica in the Caribbean basin]","volume":"165","author":"Cabre","year":"2009","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.msard.2022.103919_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102558","article-title":"Acute optic nerve lesions in first-ever NMOSD-related optic neuritis using conventional brain MRI: A Latin American multicenter study","volume":"46","author":"Carnero Contentti","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"10.1016\/j.msard.2022.103919_bib0027","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.neurol.2020.07.019","article-title":"Area postrema syndrome as initial manifestation in neuromyelitis optica spectrum disorder patients: A retrospective study","volume":"177","author":"Zhou","year":"2021","journal-title":"Rev. Neurol. (Paris)"},{"issue":"1","key":"10.1016\/j.msard.2022.103919_bib0028","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/jamaneurol.2014.2137","article-title":"Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders","volume":"72","author":"Flanagan","year":"2015","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.msard.2022.103919_bib0029","article-title":"Siriraj Neuroimmunology Research Group. Differences in clinical features between optic neuritis in neuromyelitis optica spectrum disorders and in multiple sclerosis","volume":"4","author":"Srikajon","year":"2018","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"3","key":"10.1016\/j.msard.2022.103919_bib0030","article-title":"Epidemiology of neuromyelitis optica in Latin America","volume":"3","author":"Alvarenga","year":"2017","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"6","key":"10.1016\/j.msard.2022.103919_bib0031","doi-asserted-by":"crossref","first-page":"e607","DOI":"10.1212\/NXI.0000000000000607","article-title":"Late-onset neuromyelitis optica spectrum disorder: The importance of autoantibody serostatus","volume":"6","author":"Sepulveda","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"8","key":"10.1016\/j.msard.2022.103919_bib0032","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1001\/archneurol.2012.249","article-title":"Effects of age and sex on aquaporin-4 autoimmunity","volume":"69","author":"Quek","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2022.103919_bib0033","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.msard.2018.11.008","article-title":"Autoimmune diseases associated with Neuromyelitis Optica Spectrum Disorders: A literature review","volume":"27","author":"Shahmohammadi","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.msard.2022.103919_bib0034","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/mus.21197","article-title":"Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica","volume":"39","author":"McKeon","year":"2009","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.msard.2022.103919_bib0035","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.amjmed.2012.09.014","article-title":"The clinical utility of a positive antinuclear antibody test result","volume":"126","author":"Abeles","year":"2013","journal-title":"Am. J. Med."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822004308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822004308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:00:58Z","timestamp":1761901258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822004308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":35,"alternative-id":["S2211034822004308"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.103919","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and paraclinical profile of neuromyelitis optic spectrum disorder in a peruvian cohort","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.103919","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103919"}}